30 The convergent validity of the two frailty assessment instruments was tested by correlating the measures with each other and other health status measures
The PlexusDx Precision Peptide Genetic Test identifies variations in genes affecting peptide pathways, inflammation, and metabolic efficiency
This is the first time the GIP/GLP-1 advantage over GLP-1 alone has been proven in a direct comparison, and it is why I treat "tirzepatide beats semaglutide" as a settled question rather than an open debate
Through our personalized programs, we connect you with licensed providers who understand the nuances of GLP-1 therapy, including the practicalities of living your life while on medication
Health Canada review has historically trailed FDA approval by roughly 6 to 18 months for this drug class, which is where the late-2027-to-mid-2028 window comes from
No validated PHQ-2 or PHQ-9 , no dedicated eating-disorder screen, no blood pressure or resting heart rate , no diet history beyond the single 3-option lifestyle self-rating, no exercise history , no broader comorbidity multi-select for hypertension, sleep apnea, NAFLD, PCOS, or GERD, no AUDIT-C -style alcohol quantity-frequency questions, no recreational drug naming (cocaine, opioids, kratom, methamphetamine, cannabis are not asked separately), no pregnancy or breastfeeding screen, no cardiac sudden-death family history , no MEN-2 named separately , no ID upload , and no phone OTP